Results 121 to 130 of about 306,297 (267)

Analysis of the effect of the pre-examination and triage system in patients with fever in the fever outpatient clinic. [PDF]

Front Med (Lausanne)
Li Y, Liu Y, Zhou Y, Xu X, Li Y, Zhang W.   +5 more
europepmc   +1 more source

A new Patient‐Reported Outcome Scale to assess autoimmune Encephalitis: PROSE

Annals of Neurology, EarlyView.
Objective Autoimmune encephalitis (AIE) has long‐lasting effects. Generic clinical assessment‐scales insufficiently capture disease‐specific sequelae. Patient‐reported outcome measures (PROMs) assess outcomes important to patients, ensuring relevance in the clinic and trials.
Juliette Brenner, Yvette S. Crijnen, Ilse Kulderij, Sammy H.C. Olijslagers, Cinthia J. Ruhe, Anke A.G. Tolido, Laura P. Kersten, Julia C.P. Verkoelen, Chelsey N. Kret, Brigit Thomassen, Finn I. van Wijnen, Juna M. de Vries, Tessa M. Bienfait, Tessa Brand, Jeroen Kerstens, Robin W. van Steenhoven, Anna E. M. Bastiaansen, Marienke A.A.M. de Bruijn, Agnes van Sonderen, Sharon Veenbergen, Ava Easton, Peter A. E. Sillevis Smitt, Esther van den Berg, Melissa Mandarakas, Maarten J. Titulaer   +24 more
wiley   +1 more source

Alcohol and Steatosis: The Japanese Paradox

EBioMedicine, 2016
A. Lonardo, S. Ballestri, D. Romagnoli, F. Nascimbeni   +3 more
doaj   +1 more source

Performance of a Screening Mammography AI Algorithm Repurposed for Symptomatic Mammography in a Tertiary Outpatient Clinic. [PDF]

Diagnostics (Basel)
Ngo H, Niller E, Schmitz E, Kotter E, Windfuhr-Blum M, Neubauer C, Palacios AL, Bamberg F, Neubauer J, Weiss J, Wilpert C.   +10 more
europepmc   +1 more source

Two Years of Ocrelizumab Treatment in Black and Hispanic People with Multiple Sclerosis in CHIMES: A Single‐Arm Clinical Trial

Annals of Neurology, EarlyView.
Objective To evaluate the effectiveness and safety of ocrelizumab in self‐identified black and Hispanic people with relapsing multiple sclerosis. Methods The Characterization of Ocrelizumab in Minorities with Multiple Sclerosis (CHIMES) trial, a prospective, open‐label, single‐arm, phase 4 study, intentionally recruited underrepresented populations in ...
Lilyana Amezcua, Anthony T. Reder, Evanthia Bernitsas, Nancy L. Monson, Timothy Vartanian, Gregory F. Wu, Mansoor Saleh, Annette Okai, Ahmed Z. Obeidat, Dilraj Sokhi, Rikisha Parekh, Jinglan Pei, Christopher Harp, David Clayton, Ibraheem Abioye, Mitzi J. Williams, for the CHIMES Study Group   +16 more
wiley   +1 more source

Lung POCUS in a Pulmonary Outpatient Clinic: Balancing Utility and Feasibility. [PDF]

POCUS J
Sridhar P, Patrawalla P, Kim B.
europepmc   +1 more source

Healing Integrity Determines Meniscal Extrusion After Isolated Medial Meniscus Posterior Root Repair in Knees With No Lower Limb Malalignment

Arthroscopy, EarlyView.
Purpose To investigate changes in meniscal extrusion and meniscal healing status following root repair, and the relationship between meniscal extrusion and healing conditions. Methods Patients who underwent isolated root repair between 2019 and 2023 and consented to undergo second‐look arthroscopy to evaluate their healing condition (1 year ...
Jin Seong Kim, Ui Jae Hwang, Chang Woo Woo, Choong Hyeok Choi, Kyu Sung Chung   +4 more
wiley   +1 more source

Prophylactic Enoxaparin Reduces Symptomatic Venous Thromboembolism Compared With No Chemoprophylaxis Within 95 Days After Knee Arthroscopy

Arthroscopy, EarlyView.
Purpose To investigate whether prophylactic use of low‐molecular‐weight heparin (enoxaparin) after knee arthroscopy reduces the incidence of symptomatic venous thromboembolism (VTE) compared with no postoperative pharmacological prophylaxis. Methods We conducted a population‐based cohort study using linked national insurance and hospital data from ...
Aylin Albrecht, Lorenz Kapral, Felix Gruber, Christoph Dibiasi, Oliver Kimberger, Christian Albrecht   +5 more
wiley   +1 more source

Early Post-TAVI Physical Activity After Eccentric Training Compared to Standard Practice – Results of a Feasibility Study

Clinical Interventions in Aging
Anja Haase-Fielitz,1– 3 Josefine Stoll,4 Tilman Engel,4 Claudia Beckendorf,4 Michael Haase,5– 7 Tanja Kücken,1,2 Michael Neuß,1,2 Christian Butter1,2 1Department of Cardiology, University Hospital Heart Centre Brandenburg, Brandenburg Medical School (MHB)
Haase-Fielitz A, Stoll J, Engel T, Beckendorf C, Haase M, Kücken T, Neuß M, Butter C   +7 more
doaj  

Coverage Generosity of Novel Antirheumatic Drugs in Medicare Advantage and Stand‐Alone Part D Plans

Arthritis &Rheumatology, EarlyView.
Objective We examine coverage of self‐administered disease‐modifying antirheumatic drugs (DMARDs) in Medicare Part D. Methods Using 2022–2026 Part D formulary data, we assessed coverage of the following DMARD classes that treat relapsed rheumatoid arthritis (RA): tumor necrosis factor (TNF) inhibitors, T cell costimulatory modulator, interleukin‐6 (IL ...
Youngmin Kwon, Robert W. Corty, Stacie B. Dusetzina   +2 more
wiley   +1 more source